Public, Private Sector Collaboration Essential to Aducanumab's Success in Alzheimer Disease: Ian Kremer, LEAD Coalition

This is the start of a journey in scientific exploration, not the end. We have to redouble our efforts on the science to take advantage of this moment for what can, but is not guaranteed to follow.

Biogen has seemingly cleared its biggest hurdle in its journey to bring aducanumab to the public; however, much work is left to be done in order to ensure that people who may benefit from the anti-amyloid Alzheimer disease treatment have access to it and others that are likely to come in its wake.

Access means many things, according to LEAD Coalition executive director Ian Kremer, who urged Congress to increase funding for Alzheimer dementia research at the National Institutes of Health and to work to ensure that the necessary steps that can lead to early diagnosis of Alzheimer disease are covered by Medicare.

In an interview with NeurologyLive, Kremer pointed out the collaborative team approach that needs to exist in order to provide better care for people at risk for Alzheimer disease and those with the degenerative disease.